About Us
Kolfarma was born in 2009 from research carried out at the University of Genoa on the potential anti-epileptic effect of a milk whey protein, Alpha-Lactalbumin (ALAC) .
Results obtained from clinical studies of serotonin reuptake inhibitor (SSRI) antidepressant drugs on epileptic patients lead to the search for another way to increase the synthesis of serotonin in the central nervous system (CNS), and not its time of action as reported for these drugs. ALAC is identified for this action.
Our commitment
Kolfarma is dedicated to the development of innovative solutions, investing in research and redefining therapeutic and diagnostic paths to improve people's lives.
Sustainability
Our approach consists of creating value for all stakeholders, in order to guarantee a positive and sustainable long-term impact for the system.
Transparency
Our scientific knowledge, our expertise and our innovative spirit are dedicated to achieving a better quality of life.
Food supplements
The food supplement line is based on ALAC, a colostrum whey protein and other molecules with synergistic actions with it.
Foods for special medical purposes
In addition to food supplements, Kolfarma has developed Foods for Special Medical Purposes (AMFS)
for the treatment of drug-resistant epilepsies.
The Microbiota
Prevention and Treatment for Complete Wellbeing
THE MICROBIOTA
It is made up of a number of bacteria that are 10 times our cells, viruses, which are 100 times, yeasts, fungi… it performs control functions and provides us with 3-4 million genetic units, vs. our 27,000.
PREVENTION
For good prevention it is sufficient to maintain a strong microbiota, that is
highly biodiverse in its bacterial strains.
THE TREATMENT
A strong microbiota is capable of keeping us healthy and more and more studies report that the most important characteristic is its high biodiversity of bacterial strains, rather than the type of strains present.
Patient support program
For several years there has been intense talk about the centrality and active involvement of the patient in his or her own treatment path. Placing an individual in this position necessarily entails a social responsibility: the deployment of solidarity forces that are involved in the design of services and products aimed at him or her, offering, at the same time, new tools to manage the complex experiences that the patient finds himself or herself living.